QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 azenta-collaborates-with-precede-foundation-to-offer-storage-of-study-samples-in-biorepository-and-streamline-logistics-for-diagnostics-patient-survival

Azenta, Inc. (Nasdaq: AZTA) today announced a strategic partnership with the PRECEDE Foundation, an international, multi-instit...

 jefferies-upgrades-azenta-to-buy-raises-price-target-to-38

Jefferies analyst Matthew Stanton upgrades Azenta (NASDAQ:AZTA) from Hold to Buy and raises the price target from $30 to $38.

 raymond-james-upgrades-azenta-to-outperform-announces-35-price-target

Raymond James analyst Andrew Cooper upgrades Azenta (NASDAQ:AZTA) from Market Perform to Outperform and announces $35 price ...

 evercore-isi-group-maintains-in-line-on-azenta-lowers-price-target-to-33

Evercore ISI Group analyst Vijay Kumar maintains Azenta (NASDAQ:AZTA) with a In-Line and lowers the price target from $35 to...

 azenta-q3-adj-eps-019-beats-013-estimate-sales-144000m-miss-149227m-estimate

Azenta (NASDAQ:AZTA) reported quarterly earnings of $0.19 per share which beat the analyst consensus estimate of $0.13 by 43.94...

Core News & Articles

Azenta, Inc. (NASDAQ:AZTA) today announced that it has entered a collaboration with Frenova, a division of Fresenius Medical Ca...

 evercore-isi-group-maintains-in-line-on-azenta-raises-price-target-to-35

Evercore ISI Group analyst Vijay Kumar maintains Azenta (NASDAQ:AZTA) with a In-Line and raises the price target from $29 to...

 azenta-life-sciences-partners-with-form-bio-to-advance-aav-gene-therapy-development

Integrated solution aims to reduce time and cost to lead candidates, advancing safer and more effective gene therapies to patie...

 needham-maintains-buy-on-azenta-lowers-price-target-to-40

Needham analyst David Saxon maintains Azenta (NASDAQ:AZTA) with a Buy and lowers the price target from $59 to $40.

 azenta-q2-adj-eps-005-misses-007-estimate-sales-14300m-beat-14091m-estimate

Azenta (NASDAQ:AZTA) reported quarterly earnings of $0.05 per share which missed the analyst consensus estimate of $0.07 by 28....

 evercore-isi-group-maintains-in-line-on-azenta-raises-price-target-to-52

Evercore ISI Group analyst Vijay Kumar maintains Azenta (NASDAQ:AZTA) with a In-Line and raises the price target from $50 to...

 needham-maintains-buy-on-azenta-raises-price-target-to-59

Needham analyst David Saxon maintains Azenta (NASDAQ:AZTA) with a Buy and raises the price target from $55 to $59.

 stocks-rebound-google-eyes-worst-drop-in-a-year-gold-shatters-fresh-records-whats-driving-markets-wednesday

Wall Street rose on Wednesday, with all major equity indices advancing as investors assessed the latest batch of corporate earn...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION